27
Participants
Start Date
September 1, 2019
Primary Completion Date
March 31, 2030
Study Completion Date
March 31, 2030
JR-141
IV infusion, 2.0 mg/kg/week
Fukui Clinical site, Fukui
Fukuoka Clinical site 2, Fukuoka
Fukuoka Clinical site, Fukuoka
Gifu Clinical site, Gifu
Hiroshima Prefectural Hospital, Hiroshima
Hokkaido Clinical site, Hokkaido
Kananagawa Ckinical site, Kanagawa
Kumamoto Clinical site, Kumamoto
Okayama Clinical site, Okayama
Okayama Clinical site 2, Okayama
Okinawa Clinical site, Okinawa
Osaka Clinical site 3, Osaka
Osaka Clinical site 2, Osaka
Osaka Clinical site, Osaka
Saitama Clinical site, Saitama
Shizuoka Clinical site, Shizuoka
Shizuoka Clinical site 2, Shizuoka
Tochigi Clinical site, Tochigi
Tokyo Clinical site, Tokyo
Tottori Clinical site, Tottori
Lead Sponsor
JCR Pharmaceuticals Co., Ltd.
INDUSTRY